Streetbeat News

Equity Actions

MTEM

Molecular Templates, Inc. has announced a $9.5 million private placement offering and an agreement to amend the second tranche of its July 2023 purchase agreement. This move is aimed at bolstering the company's financial position and supporting its ongoing projects.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 12:11 pm

CMPS

Compass Pathways co-founders George Goldsmith and Ekaterina Malievskaia have resigned from the board, effective March 29, 2024. David Norton will serve as interim chair while the company searches for a permanent replacement. The company highlights its progress in developing psilocybin treatment for treatment-resistant depression and its achievements under the leadership of Goldsmith and Malievskaia, including FDA Breakthrough Therapy Designation and successful financing rounds.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 12:09 pm

NRXP

NRx Pharmaceuticals has announced a 1-for-10 reverse stock split in an effort to maintain its Nasdaq listing. This corporate action is a strategic move to comply with Nasdaq's minimum bid price requirement.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 12:03 pm

PAR

PAR Technology (NYSE:PAR) has been evaluated by 6 analysts over the last three months, showing a positive shift in sentiment with 5 bullish and 1 indifferent rating recently. The average 12-month price target for PAR has increased to $54.5, up 15.15% from $47.33. The company's financial overview indicates a revenue growth of 10.3% as of December 31, 2023, but struggles with profitability and debt management, having a net margin of -17.3% and a debt-to-equity ratio of 1.15.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 12:00 pm

BRZE

Braze (NASDAQ:BRZE) received mixed analyst ratings with an updated average 12-month price target of $67.17, reflecting a slight increase from the previous target. The company's financial performance shows a revenue growth rate of 33.11% but falls below industry averages in net margin, ROE, and ROA, indicating potential profitability and efficiency challenges.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 12:00 pm

DIS

The Walt Disney Company has called on its shareholders to vote using the white proxy card in favor of its 12 director nominees to safeguard their investments and the company's future.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 11:52 am

NCNA

NuCana announced a 1-for-25 ADS ratio change, leading to its shares trading lower.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 11:45 am

GILD

XLO

Xilio Therapeutics' stock price increased following the announcement of an exclusive license agreement with Gilead Sciences for a tumor-activated IL-12 program. Additionally, Xilio announced an $11.3 million private placement equity financing.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 11:41 am

MCRB

Seres Therapeutics announced inducement equity grants of 700,000 shares to Marella Thorell, the new Executive Vice President and CFO, on March 25, 2024, as decided by the Compensation and Talent Committee of Seres' Board of Directors.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 11:27 am

XLO

Xilio Therapeutics has announced an $11.3 million private placement equity financing, indicating a significant capital infusion for the company.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 11:08 am